BIOCIUS and Agilent launch RF360 High Resolution System for high-throughput screening of in vitro ADME assays

BIOCIUS Life Sciences, Inc. and Agilent Technologies Inc. (NYSE: A) today announced the launch of the RF360 High Resolution System for high-throughput screening of in vitro ADME assays. Combining the accurate mass capabilities of Agilent's time-of-flight (TOF) mass spectrometers and the unprecedented sample processing speed of RapidFire® technology, the instrument revolutionizes in vitro ADME analysis by eliminating the method development bottleneck in drug discovery.

“Only TOF spectrometry can meet the scan speed and resolution demands required for these high-throughput types of applications”

The latest addition to the RapidFire portfolio, the RF360 High Resolution system, will be on display in the BIOCIUS hospitality suite at the 58th Annual American Society for Mass Spectrometry Conference in Salt Lake City, Utah from May 23rd to May 27th. "High resolution mass spectrometry coupled with the unparalleled sample preparation throughput of the RapidFire platform enables significant streamlining of in vitro ADME assays," said Can 'Jon' özbal, chief operating officer of BIOCIUS. "Extending our partnership with Agilent Technologies, the leader in TOF mass spectrometry allows us to completely eliminate the bottleneck of developing test-compound specific mass spectrometry methods." This revolutionary approach to in vitro ADME has been demonstrated to reduce analysis time to a fraction of that of conventional methods while requiring a minimal amount of operator input.

RapidFire technology combined with TOF mass spectrometers enables a wide range of ADME assays, including drug-drug interaction, metabolic stability, Caco-2, PAMPA and others. When performing such assays with the RF360, a priori knowledge of the test compound is not required, as data is acquired in full scan TOF-MS mode. Post acquisition, the relevant data is extracted using RapidFire software, eliminating the time consuming and labor intensive steps of LC/MS method development and batch analysis.

"Only TOF spectrometry can meet the scan speed and resolution demands required for these high-throughput types of applications," said Gustavo Salem, vice president and general manager of Agilent's Biological Systems Division. "Partnering with BIOCIUS on the RF360 has provided a solution that is the fastest approach to ADME on the market."

Representatives from BIOCIUS and Agilent will be at the ASMS Conference at booth numbers 67 and 68, respectively. The RF360 High Resolution System will be on display in BIOCIUS Hospitality suite, 251A, at the Salt Palace Convention Center. Additionally, oral and poster presentations will feature the instrumentation:

ORAL PRESENTATION:

Session: Increasing Throughput for ADME and PK Assays

8:50 a.m., Monday June 24th, Hall 2

Reducing Bottlenecks in ADME Sample Analysis using Solid Phase Extraction with a Quadrupole Time-of-Flight Mass Spectrometer. Panos Hatsis, Michelle Romm, Vaughn Miller, Jakal Amin, William A. LaMarr, Can "Jon" Ozbal, Shawn Harriman. Novartis Institutes for Biomedical Research, Cambridge, MA; BIOCIUS Lifesciences, Woburn, MA

POSTERS:

1. Session: TP21, Drug Metabolism: High Throughput

Number: 498, Tuesday June 25th

Evaluation of Accurate Mass TOF-MS for Use in High Throughput PAMPA Screening. Michelle Romm, Nikunj Parikh, Vaughn Miller, William A. LaMarr, Can "Jon" Ozbal. BIOCIUS Life Sciences, Inc., Woburn, MA

2. Session: TP21, Drug Metabolism: High Throughput Time

Number: 500, Tuesday June 25th

Comparison of LC/MS/MS and a Fully Integrated Autosampler/Solid Phase Extraction System for the Analysis of Permeability Samples. Adam C Amaral, Christopher Caldwell, Panos Hatsis, Jakal Amin, Shawn Harriman. Novartis, Cambridge, MA

3. Session: ThP24, High Throughput Analysis/Robotics

Number: 572, Thursday June 27th.

Development of a High-Throughput MS-Based Bioanalytical Method for Assessment of P-Glycoprotein Inhibition Andrew Wagner, Janet Kolb, John Herbst, Tatyana Zvyaga, Conway Charlie, Harold Weller, Wilson Shou, Can "Jon" Ozbal. Bristol-Myers Squibb Company, Wallingford, CT; Bristol-Myers Squibb Company, Princeton, NJ; BIOCIUS Life Sciences, Inc, Woburn, MA.

USER GROUP MEETING:

Agilent Technologies

Saturday, May 22, 2010

5:00 pm - 9:30 pm

Marriott City Center

Olympus and Capital Ballrooms

220 South State St.

SLC, 84111

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Evident Corporation - Life Sciences. (2019, June 24). BIOCIUS and Agilent launch RF360 High Resolution System for high-throughput screening of in vitro ADME assays. News-Medical. Retrieved on December 23, 2024 from https://www.news-medical.net/news/20100520/BIOCIUS-and-Agilent-launch-RF360-High-Resolution-System-for-high-throughput-screening-of-in-vitro-ADME-assays.aspx.

  • MLA

    Evident Corporation - Life Sciences. "BIOCIUS and Agilent launch RF360 High Resolution System for high-throughput screening of in vitro ADME assays". News-Medical. 23 December 2024. <https://www.news-medical.net/news/20100520/BIOCIUS-and-Agilent-launch-RF360-High-Resolution-System-for-high-throughput-screening-of-in-vitro-ADME-assays.aspx>.

  • Chicago

    Evident Corporation - Life Sciences. "BIOCIUS and Agilent launch RF360 High Resolution System for high-throughput screening of in vitro ADME assays". News-Medical. https://www.news-medical.net/news/20100520/BIOCIUS-and-Agilent-launch-RF360-High-Resolution-System-for-high-throughput-screening-of-in-vitro-ADME-assays.aspx. (accessed December 23, 2024).

  • Harvard

    Evident Corporation - Life Sciences. 2019. BIOCIUS and Agilent launch RF360 High Resolution System for high-throughput screening of in vitro ADME assays. News-Medical, viewed 23 December 2024, https://www.news-medical.net/news/20100520/BIOCIUS-and-Agilent-launch-RF360-High-Resolution-System-for-high-throughput-screening-of-in-vitro-ADME-assays.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Olympus Discovery Center brings advanced microscopy to brain research